TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39270747

Group type: EXPERIMENTAL
Intervention: Autism Eats program
Number of subjects: 51
Study: 39270828

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) for oligoprogressive disease in 1 to 5 fractions while maintaining systemic therapy (ST)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 70
Study: 39270937

Group type: EXPERIMENTAL
Intervention: Machine learning models using 20-40 predictors
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Machine learning models for multiclass classification
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regression models using 36 variables
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Identification of predictors
Number of subjects: 12
Study: 39270940

Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI with severe MR
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI with moderate MR
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI with mild MR
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI with no or trace MR
Number of subjects: 631

Group type: COMPARATOR
Intervention: Control group (other degrees of MR)
Number of subjects: 631
Study: 39271104

Group type: EXPERIMENTAL
Intervention: Subcutaneous daptomycin (10 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous daptomycin (10 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Subcutaneous placebo (NaCl 0.9%)
Number of subjects: 12
Study: 39271158

Group type: EXPERIMENTAL
Intervention: Somapacitan 0.16 mg/kg/week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Somapacitan 0.20 mg/kg/week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Somapacitan 0.24 mg/kg/week
Number of subjects: 62

Group type: COMPARATOR
Intervention: Daily GH 0.035 mg/kg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Daily GH 0.067 mg/kg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Somapacitan
Number of subjects: 62

Group type: COMPARATOR
Intervention: Daily GH
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Somapacitan and Daily GH
Number of subjects: 62
Study: 39271520

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 46
Study: 39271521

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily
Number of subjects: 60
Study: 39271642

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) using EYE-LIGHT
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 76
Study: 39271844

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study: 39271927

Group type: EXPERIMENTAL
Intervention: Wearable sensor data (step count, resting heart rate, sleep quantity)
Number of subjects: 553
Study: 39271928

Group type: EXPERIMENTAL
Intervention: ICVB-1042 administered intravenously or intratumorally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICVB-1042 administered intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICVB-1042
Number of subjects: 0
Study: 39271938

Group type: EXPERIMENTAL
Intervention: Self-monitored use (SM)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Peer-supported use (PS)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Clinically integrated model (CI)
Number of subjects: 558
Study: 39271956

Group type: EXPERIMENTAL
Intervention: Individuals with SLOS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher severity scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower initial cholesterol levels
Number of subjects: 0
Study: 39272058

Group type: EXPERIMENTAL
Intervention: F-627 (efbemalenograstim alfa) 20 mg once per cycle
Number of subjects: 239

Group type: COMPARATOR
Intervention: Filgrastim (5 µg/kg/d) daily
Number of subjects: 239
Study: 39272087

Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence assessment of vascular supply of post-resection pancreatic remnant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-risk group for pancreatic fistula development
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative data collection
Number of subjects: 0
Study: 39272101

Group type: EXPERIMENTAL
Intervention: 1.5-mA transcranial direct current stimulation (tDCS) targeting the left dorsolateral prefrontal cortex (F3) and right frontopolar cortex (Fp2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study: 39272117

Group type: EXPERIMENTAL
Intervention: Patient engagement in the RECOVAC project
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient engagement process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient representatives' involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guideline for patient engagement
Number of subjects: 0
Study: 39272114

Group type: EXPERIMENTAL
Intervention: 15-week resistance training intervention (RTI)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (CG) with unchanged low physical activity
Number of subjects: 57
Study: 39272125

Group type: EXPERIMENTAL
Intervention: P-STEP® mobile app
Number of subjects: 380
Study: 39272144

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional rotary instruments
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 21
Study: 39272164

Group type: EXPERIMENTAL
Intervention: Cooperative medication reviews conducted by MipAC physicians, supervised by geriatricians, and in collaboration with general practitioners
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care at the MipAC unit
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cooperative medication reviews
Number of subjects: 100
Study: 39272196

Group type: EXPERIMENTAL
Intervention: CGA-based multicomponent personalized preventive program (PPP)
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 1216
Study: 39272210

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive Remediation Therapy (TCRT)
Number of subjects: 13
Study: 39272232

Group type: EXPERIMENTAL
Intervention: Positive CD serology screening for antitissue transglutaminase antibodies in individuals with predisposing HLA-DQ2/DQ8 genotypes.
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: Caucasian ethnicity
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: Other ethnicity
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: Unknown ethnicity
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: East Asian ethnicity
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: South Asian ethnicity
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: HLA risk genotypes
Number of subjects: 2832
Study: 39272766

Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Number of subjects: 0
Study: 39273147

Group type: EXPERIMENTAL
Intervention: Circulating neoplastic-immune hybrid cells (CHCs) identified by co-expression of pan-cytokeratin (CK) and CD45, levels correlated to clinical disease course.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Treatment-resistant CHCs
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Post-trial surveillance
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Machine learning analysis of CHCs
Number of subjects: 5
Study: 39273470

Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 38
Study: 39274199

Group type: EXPERIMENTAL
Intervention: Sarcopenia definitions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscle power reduction
Number of subjects: 0
Study: 39274238

Group type: EXPERIMENTAL
Intervention: Task-Specific Perceived Harmfulness
Number of subjects: 0
Study: 39274500

Group type: EXPERIMENTAL
Intervention: Small Step Early Intervention Program
Number of subjects: 0
Study: 39275135

Group type: EXPERIMENTAL
Intervention: Portfolio Diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Diet
Number of subjects: 0
Study: 39275279

Group type: EXPERIMENTAL
Intervention: Si.Pi.Mi (silymarin, pyrroloquinoline quinone sodium salt, and myricetin)
Number of subjects: 20
Study: 39275314

Group type: EXPERIMENTAL
Intervention: FX supplementation
Number of subjects: 43
Study: 39276176

Group type: EXPERIMENTAL
Intervention: MK-8353 plus pembrolizumab (arm A; MK-8353 50-350 mg twice daily)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: MK-8353 plus pembrolizumab (arm B; MK-8353 50-600 mg once daily)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: MK-8353 plus pembrolizumab (arm C; MK-8353 50-300 mg once daily every other week)
Number of subjects: 110
Study: 39276185

Group type: EXPERIMENTAL
Intervention: Iparomlimab (3 mg/kg, intravenous, once every 3 weeks)
Number of subjects: 71
Study: 39276275

Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS)
Number of subjects: 16
Study: 39276443

Group type: EXPERIMENTAL
Intervention: Online education program based on Individual and Family Self-Management Theory
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 72
Study: 39276619

Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF/RSV preF protein vaccine (different doses of Ad26.RSV.preF with fixed dose of RSV preF protein 150 μg)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 39276782

Group type: EXPERIMENTAL
Intervention: Real-time estimation of antibody kinetics against SARS-CoV-2 variants (delta, BA.2, XBB 1.5)
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Real-time dataset of neutralising-antibody titres
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Retrospective dataset of neutralising-antibody titres
Number of subjects: 968
Study: 39276785

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks until disease progression
Number of subjects: 41
Study: 39276867

Group type: EXPERIMENTAL
Intervention: ILM peeling (n=8)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No ILM peeling (n=5)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ILM peeling
Number of subjects: 13
Study: 39277028

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 146
Study: 39277029

Group type: EXPERIMENTAL
Intervention: Management of heart failure patients at high risk for hyperkalemia
Number of subjects: 2558
Study: 39277116

Group type: EXPERIMENTAL
Intervention: LEAP2 concentration in human milk
Number of subjects: 52

Group type: COMPARATOR
Intervention: Maternal weight status (normal weight vs overweight/obesity)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Infant plasma LEAP2 concentration
Number of subjects: 52
Study: 39277170

Group type: EXPERIMENTAL
Intervention: Bouge Grossesse application (coaching program and a pedometer; n=125)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo application (pedometer only; n=125)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Bouge Grossesse application
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 250
Study: 39277203

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention involving Orthodox priests and Health Development Army members conducting community health outreach.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 300
Study: 39277672

Group type: EXPERIMENTAL
Intervention: Datopotamab-deruxtecan plus durvalumab (block A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Datopotamab-deruxtecan plus durvalumab (after blocks A + B)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 106
Study: 39277671

Group type: EXPERIMENTAL
Intervention: Datopotamab-deruxtecan (Dato-DXd)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sequential multiple assignment randomization trial design including three blocks: block A (experimental agent), block B (taxane-based regimen), block C (doxorubicin-cyclophosphamide)
Number of subjects: 103
Study: 39277739

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (15 µg/subtype/0.5 ml/dose)
Number of subjects: 1399
Study: 39277837

Group type: EXPERIMENTAL
Intervention: Physical stabilization with thoracic belt
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (no thoracic belt)
Number of subjects: 36
Study: 39278126

Group type: EXPERIMENTAL
Intervention: Function-focused multicomponent exercise program (twice-weekly for 6 months)
Number of subjects: 148
Study: 39278284

Group type: EXPERIMENTAL
Intervention: Deep endotracheal intubation (DET)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional endotracheal intubation (CET)
Number of subjects: 59
Study: 39278393

Group type: EXPERIMENTAL
Intervention: Temperature control practices; 75% survey response rate, 80% sites have protocols, 62.5% have ED-specific protocols.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Use of neuromuscular blockade (NMB) during temperature control induction; 61.7% of sites induced paralysis less than 20% of the time.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Early initiation of temperature control; 83.3% of protocols emphasized early initiation, but 62.5% reported clinical nihilism as a barrier.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: NMB usage; 1 in 2 patients treated with NMB, but variability in use and timing of temperature control device initiation.
Number of subjects: 51
Study: 39278411

Group type: EXPERIMENTAL
Intervention: Vitamin D-3 supplementation (3000 IU daily)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study: 39278792

Group type: EXPERIMENTAL
Intervention: Acute coronary syndromes (ACS)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Chronic coronary syndrome (CCS)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Greater plaque burden
Number of subjects: 419
Study: 39278920

Group type: EXPERIMENTAL
Intervention: Emotional strategies used by healthcare professionals (suppressing and modifying emotions, distancing from residents)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Acknowledging emotional labour
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Organisational culture that supports emotional expression
Number of subjects: 93
Study: 39278928

Group type: EXPERIMENTAL
Intervention: VRVT plus single-vision spectacle (SVS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Only SVS without receiving VRVT (Control)
Number of subjects: 65
Study: 39278994

Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg) plus Relatlimab (480 mg) for two 4-weekly cycles
Number of subjects: 59
Study: 39279257

Group type: EXPERIMENTAL
Intervention: 5-mg dose of melatonin 1 hour before bedtime for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard sleep hygiene (≥6 hours per night, avoiding caffeine and naps in the evening)
Number of subjects: 80
Study: 39279266

Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Aspirate Concentrate (BMAC) injection during APM
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no BMAC)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BMAC group
Number of subjects: 95
Study: 39279371

Group type: EXPERIMENTAL
Intervention: Intervention group (N=162) received two 2-h interventions combining Sharing, Mind and Enjoyment (SME), Zero-time Exercises (ZTEx), positive psychology, and simple family games.
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (N=152) received interventions unrelated to SME.
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Intervention group (N=162)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (N=152)
Number of subjects: 314
Study: 39279436

Group type: EXPERIMENTAL
Intervention: Biallelic RTEL1 variants
Number of subjects: 44
Study: 39279580

Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily plus androgen-deprivation therapy (ADT)
Number of subjects: 669

Group type: COMPARATOR
Intervention: Placebo plus androgen-deprivation therapy (ADT)
Number of subjects: 669
Study: 39279639

Group type: EXPERIMENTAL
Intervention: Cagrilintide (4.5 mg, once-weekly subcutaneous injection)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg, oral)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Moxifloxacin placebo
Number of subjects: 105
Study: 39279719

Group type: EXPERIMENTAL
Intervention: Lutein (L) and zeaxanthin (Z) concentrations measured by HPLC
Number of subjects: 42
Study: 39279766

Group type: EXPERIMENTAL
Intervention: Preoperative stereotactic radiosurgery (SRS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 48
Study: 39279973

Group type: EXPERIMENTAL
Intervention: TACE + Anlotinib
Number of subjects: 38

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 38
Study: 39280033

Group type: COMPARATOR
Intervention: No RVD
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: New-onset RVD
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Normalized RVD
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Residual RVD
Number of subjects: 648
Study: 39280041

Group type: EXPERIMENTAL
Intervention: DanceMove (step-based activity)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual activities (control)
Number of subjects: 70
Study: 39280784

Group type: EXPERIMENTAL
Intervention: CG-Well online modules
Number of subjects: 100

Group type: COMPARATOR
Intervention: ISR e-bulletins
Number of subjects: 100
Study: 39280785

Group type: EXPERIMENTAL
Intervention: Multiple electroacupuncture weekly treatment group (group M) - 12 sessions (3 sessions per week)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single electroacupuncture weekly treatment group (group S) - 4 sessions (1 session per week)
Number of subjects: 80
Study: 39280787

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39280895

Group type: EXPERIMENTAL
Intervention: Clinical Monitoring Strategy
Number of subjects: 0
Study: 39280922

Group type: EXPERIMENTAL
Intervention: Next-generation mt-sDNA test
Number of subjects: 7022
Study: 39281099

Group type: EXPERIMENTAL
Intervention: toripalimab plus definitive chemoradiotherapy (CRT)
Number of subjects: 42
Study: 39281103

Group type: EXPERIMENTAL
Intervention: IQCS (Intelligent Quality-Control System)
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Routine OGD
Number of subjects: 1840
Study: 39281698

Group type: EXPERIMENTAL
Intervention: RNA exon editing
Number of subjects: 0
Study: 39281732

Group type: EXPERIMENTAL
Intervention: Modified WHO Labour Care Guide (LCG)
Number of subjects: 2011

Group type: COMPARATOR
Intervention: Partograph
Number of subjects: 2011
Study: 39281757

Group type: EXPERIMENTAL
Intervention: Lifestyle factors (diet, sleep, and physical activity) monitored using wearables and continuous glucose monitoring
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Integrated ML models using lifestyle factors
Number of subjects: 36
Study: 39281809

Group type: EXPERIMENTAL
Intervention: Female Sexual Function Index
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: International Index of Erectile Function
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Female Sexual Distress Scale-Revised
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Sexual Health
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire
Number of subjects: 362
Study: 39281971

Group type: EXPERIMENTAL
Intervention: Subcutaneous sasanlimab 300 mg once every 4 weeks (300 mg-Q4W)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Subcutaneous sasanlimab 600 mg once every 6 weeks (600 mg-Q6W)
Number of subjects: 155
Study: 39281978

Group type: EXPERIMENTAL
Intervention: Washed microbiota transplantation (WMT)
Number of subjects: 0
Study: 39282041

Group type: EXPERIMENTAL
Intervention: Prophylactic infusion of calcium gluconate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 39282367

Group type: EXPERIMENTAL
Intervention: TLR8 agonism and anti-PD-1 blockade
Number of subjects: 0
Study: 39282508

Group type: EXPERIMENTAL
Intervention: Image-guided volume of tissue activated (IG-VTA) programming
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional ring-mode programming (CP-RM)
Number of subjects: 26
Study: 39282663

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study: 39282750

Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE)
Number of subjects: 65
Study: 39282762

Group type: EXPERIMENTAL
Intervention: Fluid balance (FB) adjusted serum creatinine (SCr) values
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Persistent AKI
Number of subjects: 131
Study: 39282854

Group type: EXPERIMENTAL
Intervention: iltamiocel
Number of subjects: 311

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 311
Study: 39282896

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 866

Group type: COMPARATOR
Intervention: Chemotherapy (physician's choice)
Number of subjects: 866
Study: 39282897

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks plus placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab (3 mg/kg every 3 weeks for four doses plus placebo)
Number of subjects: 0
Study: 39282902

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks for 1 year)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 702
Study: 39282907

Group type: EXPERIMENTAL
Intervention: Ponsegromab 100 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ponsegromab 200 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ponsegromab 400 mg
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187